open access

Vol 54, No 3 (2020)
Letter to the Editors
Submitted: 2020-05-18
Accepted: 2020-05-26
Published online: 2020-06-04
Get Citation

Does amantadine have a protective effect against COVID-19?

Albert Cortés Borra1
·
Pubmed: 32495926
·
Neurol Neurochir Pol 2020;54(3):284-285.
Affiliations
  1. Hospital Vall d'Hebron, Barcelona, 08035 Barcelona, Spain

open access

Vol 54, No 3 (2020)
Letters to the Editors
Submitted: 2020-05-18
Accepted: 2020-05-26
Published online: 2020-06-04

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Does amantadine have a protective effect against COVID-19?

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 54, No 3 (2020)

Article type

Letter to the Editors

Pages

284-285

Published online

2020-06-04

Page views

9776

Article views/downloads

26350

DOI

10.5603/PJNNS.a2020.0041

Pubmed

32495926

Bibliographic record

Neurol Neurochir Pol 2020;54(3):284-285.

Authors

Albert Cortés Borra

References (7)
  1. Zhu Na, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine. 2020; 382(8): 727–733.
  2. Rodon J, Noguera-Julian M, Erkizia I, et al. Search for SARS-CoV-2 inhibitors in currently approved drugs to tackle COVID-19 pandemia. .
  3. Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Multiple Sclerosis and Related Disorders. 2020; 42: 102163.
  4. Abreu G, Aguilar M, Covarrubias D, et al. Amantadine as a drug to mitigate the effects of COVID-19. Medical Hypotheses. 2020; 140: 109755.
  5. Tipton P, Wszolek Z. What can Parkinson’s disease teach us about COVID-19? Neurol Neurochir Pol. 2020; 54(2): 204–206.
  6. Cimolai N. Potentially repurposing adamantanes for COVID‐19. Journal of Medical Virology. 2020; 92(6): 531–532.
  7. Smieszek S, Przychodzen B, Polymeropoulos M. “Amantadine disrupts lysosomal gene expression; potential therapy for COVID19”. .

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl